Health CarePharmaceuticals & Biotechnology
  • Price (IDR)1,730.00
  • Today's Change10.00 / 0.58%
  • Shares traded7.60m
  • 1 Year change18.09%
  • Beta0.9833
Data delayed at least 10 minutes, as of Oct 26 2016 05:59 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Oct 21, 2016, the consensus forecast amongst 18 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on May 02, 2016. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 18 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,600.00, with a high estimate of 2,200.00 and a low estimate of 1,250.00. The median estimate represents a -6.98% decrease from the last price of 1,720.00.


SmartText is unavailable
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Apr 29, 2016, Kalbe Farma Tbk PT reported 1st quarter 2016 earnings of 12.02 per share.
The next earnings announcement is expected on Oct 31, 2016.
Average growth rate+6.22%
Kalbe Farma Tbk PT reported annual 2015 earnings of 42.76 per share on Feb 26, 2016.
Average growth rate+8.10%
More ▼

Revenue history & estimates

PT Kalbe Farma Tbk. had 2nd quarter 2016 revenues of 5.01bn. This bettered the 4.79bn estimate of the one analyst covering the company. This was 11.91% above the prior year's 2nd quarter results.
Average growth rate+3.04%
PT Kalbe Farma Tbk. had revenues for the full year 2015 of 17.89bn. This was 2.99% above the prior year's results.
Average growth rate+13.46%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.